Other names: Rituxan, Riabni, Ruxience, Truxima
Categories: Prescription Medication
Description: Rituximab is a monoclonal antibody that targets CD20-positive B cells, used off-label for systemic lupus erythematosus (SLE), particularly in refractory cases or when there is involvement of the kidneys, central nervous system, or blood cells. Though not FDA-approved for SLE, it is often used when patients fail standard treatments like corticosteroids, mycophenolate, or azathioprine. Rituximab may be especially helpful in lupus nephritis and autoimmune cytopenias. It is administered as an IV infusion, typically in 2 doses spaced 2 weeks apart, and repeated as needed. Potential side effects include infusion reactions and increased risk of infection, including reactivation of hepatitis B.
Treatment For:
AI generated Summary: Based on the provided information, there are no user reviews available for the treatment "Rituximab" against the disease "Systemic Lupus Erythematosus." The effectiveness of this treatment cannot be determined from the given data, as there are no ratings or reviews to analyze. More user feedback and clinical studies would be needed to assess the efficacy of Rituximab in treating Systemic Lupus Erythematosus.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
